DUBLIN – Pierre Meulien will wrap up his five-year stint at the helm of Genome Canada at the end of next week, two months before he takes up the post of executive director of the Innovative Medicines Initiative (IMI), the €3.3 billion ($3.7 billion) public-private research partnership between the European Commission and the pharmaceutical industry.